Veille techno
Toute l'actualité tech, sur une page.
Sans publicité ni traqueur · projet personnel
A Suffolk County jury on Friday awarded $6 million in damages to ousted star scientist and former MIT professor David Sabatini, whose career imploded after he was accused by a much younger colleague of inappropriate sexual conduct in his…
Edwards is asking customers to return some of the delivery systems used with its Sapien M3 devices after receiving three reports of balloons bursting when inflated during the procedure.
Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.
Longevity medicine is now estimated to be a multitrillion dollar industry. But what are people paying for, and does it work? On this week’s episode of “The Readout LOUD,” STAT’s biotech podcast, we bring on STAT reporter Sarah Todd to…
Medtronic exchanged all of its remaining shares of the diabetes technology spinoff.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them . Don’t be shy.…
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to catch up on our reading…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. We’re leaving room for popcorn and intrigue tonight: The new A24 documentary, “You Can See Everything,” hits…
The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
Industry groups have worked to release guidance on artificial intelligence-backed agents in the absence of federal regulation.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Happy Friday from sunny San Diego. This is Jonathan Wosen, West Coast biotech & life sciences reporter. We’ve got a strong…
The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver.
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."
During my years as a clinical pharmacist, I thought I understood why patients stopped taking long-term medications — one of the biggest challenges in medicine. They forgot to take them, became frustrated with side effects, or didn’t fully…
Welcome to Friendly Argument, a new STAT First Opinion series in which two experts who disagree but respect each other’s point of view engage in a debate about medicine and health policy. In this installment, John E. McDonough , author of…
WASHINGTON — Changes to the annual performance review process are the latest flashpoint in tensions between federal workers across the Department of Health and Human Services and the Trump administration, federal employees told STAT. Staff…
Was world-renowned molecular biologist David Sabatini a manipulative mentor who coerced a younger colleague into sex and cultivated a hostile work culture at his research lab in Cambridge? Or was he the victim of a spurned former lover and…
Jared Eben joins EndoQuest ahead of the anticipated launch of its flexible robotic surgery system.
WASHINGTON — U.S. health officials are moving ahead with a plan to allow specialty pharmacies to produce certain peptides , a class of largely unregulated injections that have become popular among followers of Health Secretary Robert F.…
After public school teacher Gary Keblish was diagnosed with melanoma in 2019, a surgeon cut out the tumor. But he wasn’t out of the woods. In some patients, melanoma aggressively recurs after surgery, so his doctors referred him to a new…
Accelerate the timeline from gene to lead cline with new GS Ori-Go® vector Drug developers face tremendous pressure to increase efficiency and productivity, and reduce development timelines. At Lonza, focused innovation efforts aimed at…
The Department of Justice has a warning for health care executives: Don’t be another Theranos. As the Trump administration continues its fight against Medicare and Medicaid fraud, it is also expanding its investigations into corporate…
Rep. Jake Auchincloss (D-Mass.) has some advice for fellow lawmakers: unapologetically support the biotech industry, vilify insurance companies, and focus on making America a biotech research haven, instead of relying on protectionism.…
Cracking complexity: Leveraging lessons learned for future bispecific development The biologics pipeline is becoming increasingly complex as next-generation antibody formats, including bispecific antibodies (BsAbs), move rapidly toward the…
Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.
The results come as Dexcom is awaiting a decision from the Centers for Medicare and Medicaid Services to expand Medicare coverage of the devices for people with Type 2 diabetes.
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. It’s the last day of the STAT…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. I, too, wanted to express how devastated I am over losing our colleague Helen Branswell . She was kind, scrupulous…
When drugmakers Merck and Moderna announced promising results in August from a late-stage trial of adding an mRNA cancer vaccine to immunotherapy, it was heralded as potentially powerful new way of fighting tumors. But the data don’t show…
A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.
Labcorp will pick up specialty testing in women’s health as well as a blood test that assesses the likelihood of finding aggressive prostate cancer before a biopsy decision.
Zimmer distributes an exclusive version of Think’s wireless handheld miniature robotic system that works with its Persona knee system.
Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are greeting us as we prepare for another day on the road, which means we are as busy as ever hunting and gathering items of interest, as well as an…
Y ou’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Good morning health tech readers! Day…
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here . Missed the first day of Summit, but want to tune into day two? Register here . Read the rest…
This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content. Biotech investors were happy with the…
I have spent my career studying nurses and why that workforce so often fails the people it is meant to serve. But my understanding of the system changed deeply the day my daughter died . She was 21 years old. She had intellectual and…
STAT is co-publishing this investigation by CalMatters / The Markup . Shira Fischer, a physician who works in health policy in Boston, sought a speech pathologist for her child in 2022, when virtual appointments became the norm because of…
About 40% of high school students reported binge eating in the past month in a large new government survey , putting a spotlight on how widespread this common form of disordered eating is among young people in the U.S. This is the first…
Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.”
The CEO of Compass Pathways said Wednesday that the company, which is preparing to complete the submission of its psychedelic therapy for regulatory review this quarter, will “go slow before we go fast,” warning that negative patient or…
Nature Biotechnology, Published online: 15 October 2026; doi:10.1038/s41587-026-03332-9 HitSV models the interaction between genomic repetitiveness and signature intensity to improve structural variant detection.
BOSTON — Three former Food and Drug Administration chiefs lit into the Trump administration Wednesday, criticizing the now former FDA officials who oversaw a massive staffing exodus and saying they robbed the agency of institutional…
BOSTON — This fall, the Massachusetts Institute of Technology, where 95% of students are STEM majors, enrolled nearly 500 fewer graduate students — a 20% drop compared to 2024. The reduction is a direct result of a $100 million cut in…
The Trump administration is delaying by 90 days a federal rule that could prevent Americans from obtaining prescription drugs from licensed international pharmacies. The move follows growing criticism that the rule, which was initially…
Whoop has never been known for marketing to an older population. Performance athletes headline ads for the wearable company, which aims to turn continuous streams of physiological data into useful insights for behavior change — mostly, for…
In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.
Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.
In a strategy shift, the company will invest in its procedural ultrasound business, supporting cardiovascular surgeries
Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s claims.
Good morning. Yesterday, we got the devastating news that STAT’s infectious disease correspondent, Helen Branswell, passed away. She was a reporter I always looked up to and was also an incredibly generous colleague. Please take the time…
A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.
The payments were made after a California arbitrator found private text messages between Orthofix executives couldn’t be considered cause for firing.
The digital pathology firm “fits in very well” with Agilent and moves the company into a sector targeted by Roche, analysts said.
Discover why flow paths, tubing and connectors may limit your bioprocess performance
One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform the reputation for reverse mergers — quickly executing on a complicated deal.
For the second straight quarter, the cardiovascular unit experienced slower sales growth due to ongoing struggles in the Abiomed business.
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.
An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.
Building trust in AI-assisted SLR: A reinvention of systematic literature reviews Discover how AI can help modernize systematic literature reviews while maintaining the traceability and governance teams need to trust the results. Learn how…
Connected Evidence: From Insight to Impac Discover how Medical Affairs and publication teams can create greater value from scientific evidence. Explore strategies for connecting evidence planning, workflows, technology, and measurement to…
The takeover adds high-growth, high-margin products to Steris’ portfolio, analysts said.
Nature Biotechnology, Published online: 13 October 2026; doi:10.1038/s41587-026-03310-1 Chimeric antigen receptor natural killer cells to treat autoimmune disease and cancer are generated in vivo.
Nature Biotechnology, Published online: 13 October 2026; doi:10.1038/s41587-026-03361-4 Six proteomic aging clocks are deployed in a clinical trial for the first time, revealing more about the clocks than about the drug.
Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential.
Ascensia also struck an exclusive sales agreement with Sava, which is making a wearable to continuously monitor glucose and other biomarkers.
Stryker, which has been looking to get into the soft tissue robotics market for years, is now positioned to compete with new entrants Johnson & Johnson and Medtronic.
Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.
Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.
Accelerating scientific innovation and discovery with AI Discover how AI is transforming life sciences from early discovery through commercialization. Learn how secure, scalable AI workflows can help accelerate innovation, protect critical…
A software issue can delay use of the Lumify diagnostic ultrasound system in environments without access to Wi-Fi or cellular signal.
Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.
Nature Biotechnology, Published online: 12 October 2026; doi:10.1038/s41587-026-03340-9 A true multidisciplinary scientist, Bowen Li finds that some of the most interesting questions are located precisely at the boundaries between fields.
Nature Biotechnology, Published online: 12 October 2026; doi:10.1038/s41587-026-03354-3 Live-cell imaging goes WHOLISTIC
Nature Biotechnology, Published online: 12 October 2026; doi:10.1038/s41587-026-03347-2 Biotech news from around the world
Nature Biotechnology, Published online: 12 October 2026; doi:10.1038/s41587-026-03363-2 RevMed’s pancreatic cancer drug first
Nature Biotechnology, Published online: 12 October 2026; doi:10.1038/s41587-026-03349-0 FDA nod for rare neurology drug
Nature Biotechnology, Published online: 12 October 2026; doi:10.1038/s41587-026-03353-4 Tracing the origins of CRISPR–Cas
Nature Biotechnology, Published online: 12 October 2026; doi:10.1038/s41587-026-03324-9 Recent patents relating to systems, methods and compositions for use in genome editing.
Nature Biotechnology, Published online: 12 October 2026; doi:10.1038/s41587-026-03355-2 Engrafting human cortical organoids